



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : C12N 15/62, 1/19, C07K 14/47, C12Q 1/68, G01N 33/50 // C07K 14/72, 14/705</p>	<p>A1</p>	<p>(11) International Publication Number: <b>WO 99/14344</b> (43) International Publication Date: 25 March 1999 (25.03.99)</p>
<p>(21) International Application Number: PCT/GB98/02759 (22) International Filing Date: 11 September 1998 (11.09.98) (30) Priority Data: 9719496.3 13 September 1997 (13.09.97) GB (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): BROWN, Andrew, James [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Herts SG1 2NY (GB). DOWELL, Simon, Jeremy [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Herts SG1 2NY (GB). (74) Agent: LEAROYD, Stephanie, Anne; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB)."</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>
<p>(54) Title: G PROTEIN CHIMERAS</p> <p><b>G<sub>α</sub> proteins</b></p> <p><b>A. Wild-type Gpa1p:</b></p> <p>NH<sub>2</sub> ————— Gpa1p(1-472) ————— COOH</p> <p>Switch domains I II III</p> <p><b>B. Gpa1/G<sub>α</sub> Chimeras:</b></p> <p>————— Gpa1p(1-330) —————</p> <p><b>C. Gpa1/G<sub>α</sub> Transplants:</b></p> <p>————— Gpa1p(1-467) —————</p> <p><b>D. Truncated Gpa1:</b></p> <p>————— Gpa1p(1-467) —————</p> <p>Mammalian G<sub>α</sub> Mammalian G</p> <p>KIGIT</p>		
<p>(57) Abstract</p> <p>A chimeric G<sub>α</sub> protein having yeast G<sub>α</sub> (Gpa1p) amino acid sequences modified by a minimum of 3 amino acids positions within the C-terminal 10 amino acids by substitution by alternative amino acids, a transformed yeast cell comprising said chimeric G<sub>α</sub> protein and a method of screening for a compound able to interact with a receptor comprising contacting a compound of interest with said yeast cell and observing the growth response of the cell or observing production of a reporter gene product.</p>		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## G PROTEIN CHIMERAS

5 The present invention relates to chimeric G proteins, expression constructs therefor, yeast cells expressing such constructs and methods of making and using them.

10 G protein-coupled receptors are integral membrane proteins, characteristically with 7 transmembrane domains, which convey hormonal and sensory signals to the cell interior (see (1) for review). These receptors are commonly referred to as 7TM receptors or 7TMRs. The receptors respond to ligand binding by activating heterotrimeric G proteins composed of  $\alpha$ ,  $\beta$  and  $\gamma$  subunits. The  $G_\alpha$  subunit is bound to GDP in the G protein trimer, and interaction with an activated (ligand bound) receptor induces the replacement of GDP with GTP. Accompanying conformational changes result in the dissociation of  $G_\alpha$ -GTP and the  $G_\beta/\gamma$  particle, either of which can modulate ion channel or enzyme effectors to cause signal propagation. The signal persists until  $G_\alpha$ , which has GTPase activity, hydrolyses the bound GTP, allowing reassembly of the heterotrimer. Members of the RGS (Regulator of G protein Signalling) protein family regulate signal duration by acting as GAPs (GTPase activating proteins) for the  $G_\alpha$  subunit (38) (17). The G protein signalling system appears to be common to all eukaryotes.

25 A well-characterised example of the trimeric G protein signalling system is the pheromone response pathway of the budding yeast *Saccharomyces cerevisiae* (20). Cells of the *MATa* mating type express a receptor encoded by the *STE2* gene. This receptor becomes activated upon binding of the  $\alpha$ -factor mating pheromone, a peptide secreted by cells of the opposite (*MAT $\alpha$* ) mating type. The yeast G protein is assembled from the products of the *GPA1* ( $G_\alpha$ ), *STE4* ( $G_\beta$ ), and *STE18* ( $G_\gamma$ ) genes. The  $G_\beta/\gamma$  (Ste4p/Ste18p) particle released upon activation of the Ste2p receptor conveys the signal to a mitogen-activated protein kinase (MAPK) module. This leads to activation of the cyclin-dependent kinase inhibitor Far1p, causing cell cycle arrest and transcriptional induction of a set of genes involved in the mating process, including *FUS1*. The pathway is desensitised by Sst2p, a member of the RGS family. Cells of the opposite mating type (*MAT $\alpha$* ) express a different receptor (Ste3p) and thereby respond to

35

the pheromone (a-factor) secreted by *MATa* cells; otherwise the signalling apparatus utilised in the two mating types is the same.

At present, at least 16  $G_\alpha$  subunits, 5  $G_\beta$  subunits and 11  $G_\gamma$  subunits have been identified in mammals, which can assemble a wide diversity of trimeric G proteins. On the basis of sequence homology, the  $G_\alpha$  subunits fall into at least four families, related to  $G_{\alpha i}$ ,  $G_{\alpha s}$ ,  $G_{\alpha q}$ , or  $G_{\alpha 12}$ . Typically, a given 7TM receptor activates only a single or small subset of  $G_\alpha$  subunits. Thus even in cells which express multiple  $G_\alpha$  subunits, signalling may be specific to particular G proteins and their downstream signalling pathways. A combination of approaches has defined several specific regions of the  $G_\alpha$  subunit as key determinants of receptor/G protein specificity. These include regions in the N-terminus, the switch II to switch III regions (21) which are primarily responsible for binding  $G_\beta/G_\gamma$ , and particularly regions of the C-terminus. For example, a cluster of mutations occurring in the C-terminal region of  $G_\alpha$  have been found to cause defects in receptor coupling ((29)(13) and references therein). Also, peptides modelled on the C-termini of  $G_{\alpha t}$  (transducin) and  $G_{\alpha 12}$  compete for binding to rhodopsin and the  $\beta$ -adrenergic receptor, respectively (9)(30)(35) and antibodies directed against the  $G_\alpha$  C-terminus can also block interaction with receptors (6)(10)(36). The normal response to agonist stimulation of the adenosine  $A_1$  receptor in cultured mammalian cells (e.g. COS cells) is the activation of  $G_{\alpha i}$ -family proteins, resulting in inhibition of adenylate cyclase.  $G_{\alpha q}$ -containing heterotrimers in contrast do not normally respond to  $A_1$  activation. However,  $G_{\alpha q}$  subunit can be induced to interact with the  $A_1$  receptor by exchanging the C-terminal four amino acids of  $G_{\alpha q}$  for the corresponding amino acids of  $G_{\alpha 12}$  (7). Hence, phospholipase C (an effector of activated  $G_{\alpha q}$ ) can be activated by adenosine  $A_1$  receptor agonists when signalling is mediated by a chimeric  $G_\alpha$  subunit (7). The somatostatin  $SST_3$  receptor is incompatible with  $G_{\alpha s}$ , but can be coupled to the activation of adenylate cyclase in COS cells by replacement of five C-terminal amino acids of  $G_{\alpha s}$  with corresponding residues from either  $G_{\alpha 12}$ , which is known to interact with the  $SST_3$  receptor, or from  $G_{\alpha 16}$ (18).  $G_{\alpha 15}$  and  $G_{\alpha 16}$  interact with a wide range of 7TM receptors (26), and are unusual in this respect. In crystal structures which have been solved for  $G_{i1}$  (41) and  $G_t$  (19) trimers, the  $G_\alpha$  C-terminal tail lies on a flat, largely uncharged surface of the G protein trimer which also includes two lipid groups covalently attached to the  $G_\alpha$

N-terminus and the  $G_\gamma$  C-terminus. This surface is believed to face the membrane and to be involved in interactions with the intracellular loops of the 7TM receptor.

5 Several reports have demonstrated that the yeast G protein signalling system can be coupled to heterologously expressed mammalian G protein-coupled (7TM) receptors. Some receptors, including the rat somatostatin SST<sub>2</sub> receptor (33), and the rat adenosine A<sub>2a</sub> receptor (34), can interact directly with the yeast  $G_\alpha$  protein Gpa1p, whereas other receptors, including the human growth  
10 hormone releasing hormone receptor (GHRHR)(12), are incompatible with Gpa1p. In order to allow coupling of these receptors, the yeast  $G_\alpha$  subunit can be deleted and the heterologous receptor co-expressed with a full-length mammalian  $G_\alpha$  subunit. Alternatively, chimeric  $G_\alpha$  subunits have been used in which the C-terminal domain (approx. one third of the peptide sequence) of  
15 Gpa1p is replaced with the equivalent region of a mammalian  $G_\alpha$  subunit. See WO95/21925 (American Cyanamid Company) for both approaches. Chimeras, or other modified or heterologous  $G_\alpha$  subunits must satisfy several criteria to be useful in a yeast coupling system. Most importantly, they must bind efficiently to yeast  $G_\beta/G_\gamma$  to prevent signalling in the absence of activated 7TM receptor, and  
20 they must effectively interact with agonist-bound activated receptors to be capable of signal propagation.

Such heterologous or chimeric  $G_\alpha$  components can facilitate the coupling of a heterologous 7TM receptor to the yeast signalling system (the pheromone  
25 response pathway) so that the effects of ligands such as potential new drug molecules on the receptor can be observed in phenotypic responses of the yeast cells. For example, cells may be induced to grow, and/or to convert an indicator dye compound in response to receptor agonists by introducing reporter genes downstream in the signalling pathway. However, chimeric constructs such  
30 as those described in WO95/21925 commonly show reduced affinity for the yeast G protein  $\beta\gamma$  subunit pair and show increased background signalling. Because of the specificity of a given receptor for one or a small number of the known  $G_\alpha$  subunits, different  $G_\alpha$  constructs have been required to demonstrate functional coupling activity with the majority of receptors tested.

35

The discovery of new drugs able to act via 7TM receptors requires screens of high efficiency, yet high specificity. Currently, the yeast coupling system is constrained by receptor/G protein specificity which imposes a requirement for a wide variety of  $G_\alpha$  constructs to be tried for each receptor tested for coupling.

5 For receptors which fail to couple, there is uncertainty as to whether failure is due to receptor/G protein incompatibility, or other reasons such as inappropriate receptor conformation, for example. It would be desirable to be able to couple a number of different receptors to the yeast G protein signalling pathway using a single  $G_\alpha$  construct. This can be beneficial in the study of orphan receptors, of

10 which nothing is known of receptor/G protein specificity. Alternatively, an array of  $G_\alpha$  constructs could be used in the study of orphan receptors.

Surprisingly, we have found that certain chimeric G proteins, which we refer to as G protein "transplants" can be at least ten-fold more efficient than previously

15 known chimeras in coupling mammalian 7TM receptors to the yeast mating pathway.

Accordingly, in a first aspect the present invention provides a chimeric  $G_\alpha$  protein having yeast  $G_\alpha$  (Gpa1p) amino acid sequences modified by a minimum

20 of 3 amino acids positions within the C-terminal 10 amino acids by substitution with alternative amino acids. Preferably the chimera includes at least 5 such substitutions.

Accordingly, in a second aspect the present invention provides a chimeric  $G_\alpha$  protein having yeast  $G_\alpha$  (Gpa1p) amino acid sequences modified at a minimum

25 of three amino acid positions within the C-terminal 10 amino acids by substitution with amino acids from a heterologous  $G_\alpha$  protein. Preferably the chimera includes at least 5 substitutions. In preferred embodiments of this aspect of the invention, the chimera includes at least 3, desirably at least 5

30 consecutive amino acids corresponding to an amino acid sequence derived from the C-terminal 10 amino acids of a heterologous  $G_\alpha$  protein. For example, the C-terminal 5 amino acids of a mammalian  $G_\alpha$  protein, for example  $G_{\alpha 16}$ , but feasibly any  $G_\alpha$ , may replace at least the C-terminal 5 amino acids of the endogenous yeast  $G_\alpha$  protein to provide a chimera according to the invention.

35 We have designated such chimeras "transplants" or "transplant chimeras".

The chimeric  $G_\alpha$  proteins of the present invention are believed to adopt a conformation which is more compatible with signal transduction in yeast (and is presumed to be closer to the native yeast  $G_\alpha$  conformation) than that of previously known chimeras in which the C-terminal domain of the yeast protein was exchanged for that of a mammalian  $G_\alpha$  protein. Thus the chimeras of the present invention have the advantage of changing receptor specificity and permitting the coupling of diverse receptors to the yeast signalling pathway with only minimal changes to the Gpa1p sequence. As a result of the close similarity to wild-type Gpa1p, these chimeric  $G_\alpha$  subunits retain a similar affinity for  $G_\beta/\gamma$  as Gpa1p, and expression can be directed by the *GPA1* promoter to achieve an optimal stoichiometry of  $G_\alpha$ . Expression from various other promoters is also compatible with receptor coupling.

In a third aspect, the present invention also provides a nucleotide sequence encoding a chimeric  $G_\alpha$  protein according to the present invention. Also provided is an expression vector comprising said nucleotide sequence and capable of expressing the nucleotide sequence on transfection into a suitable host cell. The construction of expression vectors including suitable promoters, transcription termination sequences and marker genes will be apparent to a person skilled in the art. The host cell may desirably be a yeast cell of the species *Saccharomyces cerevisiae* and represents a further aspect of the invention.

Accordingly, the invention also provides a transformed yeast cell comprising a nucleotide sequence which encodes a chimeric  $G_\alpha$  protein according to the present invention, for example a heterologous G protein-coupled receptor including receptors for which the ligand is unknown, and a nucleotide sequence which encodes a chimeric  $G_\alpha$  protein comprising yeast  $G_\alpha$  (Gpa1p) amino acid sequences and at least 3 amino acids derived from the amino acid sequence of the C-terminal 10 amino acids of a  $G_\alpha$  protein according to the present invention for example a heterologous  $G_\alpha$  protein, such as the mammalian,  $G_{\alpha 16}$  protein. The heterologous receptor may be a 7TM receptor. Such receptors include those for acetylcholine, adrenaline, noradrenaline, dopamine, histamine, melatonin, serotonin, angiotensin, prostaglandins, cannabinoids, neuropeptide

Y, substance P, opioids, glucagon, angiotensin, bradykinin, chemokines, thrombin, glycoprotein hormones, adenosine, nucleotides, and somatostatin.

Transformed yeast cells according to the present invention may also comprise a  
5 nucleotide sequence encoding a reporter gene operatively associated with a promoter responsive to the G protein signalling pathway. Such reporter genes may include *HIS3* or other auxotrophic markers (such as *URA3*, *LEU2*, or *TRP1*) or genes which confer resistance or sensitivity to drug selections, such as *CYH2* or *G418<sup>R</sup>* or other genes such as those encoding intracellular enzymes such as  
10  $\beta$ -galactosidase (*LacZ*) and luciferase, or green fluorescent protein (GFP), or genes encoding secreted enzymes such as a phosphatase such as *PHO5*, or a kinase. Desirably, yeast cells may contain combinations of multiple reporter genes, such as *FUS1-HIS3* and *FUS1-lacZ*. In preferred embodiments the transformed yeast cells will also include mutations in at least one of the *GPA1*,  
15 *SST2* or *STE2* genes. Preferably such mutations will be deletions. Desirably, *FAR1* is also deleted when a reporter gene is used to monitor activity in the G protein signalling pathway. This ensures that growth can continue even under conditions which activate the pheromone response pathway. In alternative  
20 embodiments of this invention, the *FAR1* gene may remain intact so that agonist stimulation causing activation of the signalling pathway may be monitored as resulting in growth arrest.

Preferred yeast strains will have deletions of *SST2* and *GPA1* (yeast  $G_{\alpha}$ ) - the  
25 former to prevent down-regulation of the signal by Sst2p activation of GTP-ase, the latter to prevent signal quenching, which occurs when  $G_{\alpha}$  is present in stoichiometric excess to  $G_{\beta}/G_{\gamma}$ , due to rapid reassociation of the actively signalling  $G_{\beta}/G_{\gamma}$  moiety into the inactive heterotrimer.

We have designated the chimera between the N-terminal 467 amino acids of  
30 Gpa1p and the 5 C-terminal amino acids of  $G_{\alpha 16}$  as the Gpa1- $G_{\alpha 16}$  transplant. Similarly, the chimera containing the C-terminal 5 amino acids of  $G_{\alpha q}$  is designated as the Gpa1- $G_{\alpha q}$  transplant, and the chimera containing the C-terminal 5 amino acids of  $G_{\alpha s}$  is designated as the Gpa1- $G_{\alpha s}$  transplant. In addition, the following transplants have also been constructed. They are  
35 identical to those described above, ie. they comprise the N-terminal 467 amino



acids of Gpa1p and the C-terminal 5 amino acids from a  $G_\alpha$  protein as follows: Gpa1- $G_{\alpha 12}$ , Gpa1- $G_{\alpha 13}$ , Gpa1- $G_{\alpha 14}$ , Gpa1- $G_{\alpha i1}$ , Gpa1- $G_{\alpha i3}$ , Gpa1- $G_{\alpha 0}$  and Gpa1- $G_{\alpha z}$ .

- 5 A further transplant was prepared between the yeast  $G_\alpha$ , Gpa1p and Gpa3, a  $G_\alpha$  subunit from the yeast *Ustilago maydis*. This transplant is designated Gpa1-Gpa3. These transplants illustrate that by changing the 5 C-terminal amino acids of Gpa1p the specificity of the  $G_\alpha$  subunit for receptors can be altered. Also the results indicate that the effectiveness of the "transplants" in coupling to  
10 foreign receptors in yeast is unexpectedly good compared to chimeric subunits with longer heterologous  $G_\alpha$  regions.

- In mammalian cells, the purinergic nucleotide P2Y<sub>2</sub> receptor is coupled to the activation of phospholipase C $\beta$  (PLC $\beta$ ) via  $G_{\alpha q}$ . We have found that the Gpa1-  
15  $G_{\alpha q}$  transplant substantially improves the weak response to agonist observed with wild-type Gpa1p. Similarly, coupling of the somatostatin SST<sub>2</sub> receptor achieved with the Gpa1- $G_{\alpha 16}$  transplant was enhanced ten-fold compared to either wild-type Gpa1p or the  $G_{\alpha i/0}$  family chimeras, which is remarkable considering this receptor interacts with  $G_{\alpha i/0}$  proteins in mammalian cells. Also  
20 the 5HT<sub>1A</sub> receptor can interact with the Gpa1- $G_{\alpha 16}$  transplant, even though it fails to stimulate wild-type Gpa1p in MMY9 yeast cells. Minimal amino acid substitutions can confer on yeast Gpa1p the properties of a generic G protein ( $G_{\alpha 16}$ ) which was not possible under previously described approaches to chimera construction. Therefore this invention presents for the first time the  
25 possibility of a system comprising a single  $G_\alpha$  subunit and able to couple a wide variety of 7TM receptors.

- Moreover, we have found that the approach of substituting the five C-terminal amino acids of Gpa1p to generate the transplants is widely applicable, in that we  
30 have generated transplants of representative members of all four  $G_\alpha$  families:  $G_{\alpha i}$ ,  $G_{\alpha s}$ ,  $G_{\alpha q}$  and  $G_{\alpha 12}$ . This was not possible in previously described approaches to chimera construction. Furthermore, all of the transplants can be expressed from the promoter of the *GPA1* gene to achieve optimal stoichiometry for efficient coupling. This was not possible in previously described approaches to chimera  
35 construction, as some of these chimeras required expression from stronger

promoters, as in the case of Gpa1/G<sub>αs</sub> (ref:12). Lastly, the pheromone response pathway is not activated in cells which express integrated versions of the transplants in the absence of activated receptors. This indicates that manipulations to the C-terminal amino acids do not interfere with the interaction with G<sub>β</sub>/G<sub>γ</sub>; this was not true with previously described approaches to chimera construction. Together, our data suggest that the approach of creating transplants will be applicable to any newly discovered mammalian G<sub>α</sub>, or to G<sub>α</sub> subunits not described herein (G<sub>αt</sub> or G<sub>αolf</sub>) or to G<sub>α</sub> subunits derived from any other metazoan species.

The invention will now be further described, by way of example and illustration and not of limitation, by the following experimental examples with the aid of figures in which:

Figure 1 shows agonist-dependent growth of the modified yeast (*S. cerevisiae*) strain MMY9. Cells expressing one of four human G protein-coupled receptors illustrate the ability of these receptors to interact with and activate the endogenous yeast G<sub>α</sub> subunit (Gpa1p);

Figures 2 A-D show induction of the *FUS1-lacZ* reporter gene in response to receptor agonists using cells expressing receptor plus different modified G<sub>α</sub> subunits;

Figure 3 shows that constructs which express a Gpa1/G<sub>α16</sub> chimera (containing a large C-terminal domain derived from G<sub>α16</sub>) reduce *FUS1-HIS3* reporter gene expression to basal levels;

Figures 4 A-D show agonist-dependent activation of the *FUS1-lacZ* reporter gene by receptor agonists, mediated by Gpa1p modified at the C-terminal five residues (the transplants);

Figure 5 is a diagrammatic representation of G<sub>α</sub> subunit constructs used in this study. The switch domains are shaded. Numbers in parenthesis refer to amino acid numbers of wild-type G<sub>α</sub> subunits. Gpa1/G<sub>α</sub> chimeras in B) contained C-

terminal regions (hatched) as follows:  $G_{\alpha i1}$  (212-354),  $G_{\alpha i2}$  (213-355),  $G_{\alpha i3}$  (212-354),  $G_{\alpha 0}$  (213-354),  $G_{\alpha 16}$  (221-374),  $G_{\alpha s}$  (235-394),  $G_{\alpha q}$  (211-353);

Figure 6 (a) to 6 (h) are diagrammatic representations of certain plasmid constructs used in this study (plasmid maps);

Figure 7 shows the activity of the *FUS1-lacZ* reporter gene in MMY9 (*STE2*) and MMY11 ( $\Delta$ *STE2*) cells transformed with pRS314-Gpa1 in response to incubation with the agonist,  $\alpha$ -factor;

Figures 8 A-C show comparisons of isogenic yeast strains containing either episomal or integrated constructs expressing the transplants Gpa1- $G_{\alpha z}$  (Fig.8A), Gpa1- $G_{\alpha 13}$  (Fig.8B), and Gpa1- $G_{\alpha 12}$  (Fig.8C). Cells were deleted for the endogenous *STE2* gene but were transformed with a plasmid (Yep24-*STE2*) to express Ste2p to enable detection of *FUS1-lacZ* reporter gene activation in response to  $\alpha$ -factor.

## Materials and Methods:

### Plasmids and Strains

Nucleic acid manipulations were carried out according to standard methods (24).

### Receptor Expression Constructs

Receptor expression constructs were based on the high copy number episomal yeast-*E.coli* shuttle vectors pFL61 (27), YEp24, and pDT-PGK (see plasmid map of Fig. 6(A)), which is identical to pPGK reported by Kang *et al.* (14). Complementary DNA (cDNA) sequences encoding unmodified human G protein-coupled receptors were introduced into these vectors between the promoter and terminator regions of the *PGK1* gene, to confer strong constitutive expression in yeast cells. The somatostatin SST<sub>2</sub> receptor (Genbank accession M81830) was introduced into pFL61. The melatonin ML<sub>1B</sub> (Genbank accession U25341), somatostatin SST<sub>5</sub> (Genbank accession L14865), serotonin 5HT<sub>1A</sub> (Genbank

accession X13556), and serotonin 5HT<sub>1D</sub> (Genbank accession M81589) receptors were introduced into pDT-PGK. The purinergic nucleotide P2Y<sub>1</sub> receptor (Genbank accession S81950) and the adenosine A<sub>2b</sub> receptor (Genbank accession M97759) were also introduced into pDT-PGK. The purinergic nucleotide P2Y<sub>2</sub> receptor was also introduced into pDT-PGK. The sequence of the P2Y<sub>2</sub> receptor corresponded to that reported by Parr *et al.* (Genbank accession U07225) (32)(31) except codon 348 was GAA (Glu) and not GGA (Gly), potentially as a result of phylogenetic variation. The gene encoding the endogenous yeast  $\alpha$ -factor receptor STE2 was expressed from its own promoter using the construct Yep24-STE2.

#### G <sub>$\alpha$</sub> Expression Constructs

To create a construct for expression of sequences encoding G protein  $\alpha$  subunits, a cassette consisting of the 1 Kb upstream region of the *GPA1* gene (the *GPA1* promoter), plus a multiple cloning site and the transcription terminator region of the *ADH1* gene (*ADHt*) were inserted into the centromeric plasmid pRS314 (Stratagene), generating pJW1 (Fig. 6 (b)). The *GPA1* open reading frame was inserted into the *NruI* site of pJW1 to create the *GPA1* expression plasmid pRS314-GPA1 (Fig. 6 (c)).

#### Gpa1/G $\alpha_{i3}$ Chimera

Sequence encoding the chimeric G $\alpha$  subunit Gpa1/G $\alpha_{i3}$  was derived from the plasmid pADC2-SCGi3. The chimera encoded by this plasmid is of a structure identical to that reported by Kang *et al.* (14) (with a *Bam*HI site in the switch II domain) except that it contains the C-terminus of G $\alpha_{i3}$  rather than G $\alpha_{i2}$ . The Gpa1/G $\alpha_{i3}$  expression construct used in this study was created by PCR amplification using oligodeoxynucleotide primers to incorporate *NcoI* and *NotI* restriction enzyme sites adjacent to the open reading frame.

The sequence encoding the Gpa1/G $\alpha_{i3}$  chimera was inserted between the *NcoI* and *NotI* restriction enzyme sites of pJW1, to create the plasmid pRS314-Gpa1/G $\alpha_{i3}$  (Fig. 6 (d)). Constructs to express the Gpa1/G $\alpha_0$ , Gpa1/G $\alpha_{i1}$ , Gpa1/G $\alpha_{i2}$ , Gpa1/G $\alpha_s$ , Gpa1/G $\alpha_q$  and Gpa1/G $\alpha_{16}$  chimeras were derived from

pRS314-Gpa1/G<sub>ai3</sub> by replacing the G<sub>ai3</sub>-derived sequence (between the *Bam*HI and *Not*I restriction enzyme sites) with sequences encoding corresponding C-terminal regions of G<sub>α0</sub>, G<sub>αi1</sub>, G<sub>αi2</sub>, G<sub>αs</sub>, G<sub>αq</sub> and G<sub>α16</sub>. Plasmid maps of pRS314-Gpa1/G<sub>α0</sub>, pRS314-Gpa1/G<sub>αi1</sub>, pRS314-Gpa1/G<sub>αi2</sub>, and pRS314-Gpa1/G<sub>α16</sub> are presented in Figs 6 (e), (f), (g) and (h), respectively.

### G<sub>α</sub> Transplants

The 'transplants', which had amino acid modifications the extreme C-terminus of Gpa1p, were generated in three steps. First, the *Afl*III site located in the *GPA1* promoter of pRS314-GPA1 was removed by blunt-ending with Klenow and religation. Next, codon 467 of *GPA1* was altered from AAA to AAG by site-directed mutagenesis, which was carried out using the Quik-change kit (Stratagene). This nucleotide change introduced an *Afl*III site without changing the encoded protein sequence. Finally, the *Afl*III/*Xho*I fragment was replaced with oligodeoxynucleotide linkers created by annealing the pairs of oligodeoxynucleotides shown in Table 1.

**Table1**

Oligodeoxy-nucleotide	Sequence (5' to 3')	Transplant
Gqtop Gqbtm	TTAAGGAATACAACCTAGTTTGAATTCCG SEQ ID NO: 1 TCGACGGAATTCAAACCTAGGTTGTATTCC SEQ ID NO: 2	Gpa1/G <sub>αq</sub>
Gstop Gsbtm	TTAAGCAATACGAACCTATTGTGAATTCCG SEQ ID NO: 3 TCGACGGAATTCACAATAGTTCGTATTGC SEQ ID NO: 4	Gpa1/G <sub>αs</sub>
Gotop Gobtm	TTAAGGGTTGTGGCTTGTACTGAATTCCG SEQ ID NO: 5 TCGACGGAATTCAGTACAAGCCACAACCC SEQ ID NO: 6	Gpa1/G <sub>αo</sub>
Gi1top Gi1btm	TTAAGGATTGTGGTTTGTGTTTGAATTCCG SEQ ID NO: 7 TCGACGGAATTCAAAACAAACCACAATCC SEQ ID NO: 8	Gpa1/G <sub>αi1</sub>
Gi3top Gi3btm	TTAAGGATGTGGTTTGTACTGAATTCCG SEQ ID NO: 9 TCGACGGAATTCAGTACAAACCACATTCC SEQ ID NO: 10	Gpa1/G <sub>αi3</sub>
Gztop Gzbtm	TTAAGTATATAGGCTTGTGTTGAATTCCG SEQ ID NO: 11 TCGACGGAATTCACACAAGCCTATATAC SEQ ID NO: 12	Gpa1/G <sub>αz</sub>
G12top	TTAAGGATATTATGTTGCAATGAATTCCG SEQ ID NO: 13	Gpa1/G <sub>α12</sub>

G12btm	TCGACGGAATTCATTGCAACATAATATCC SEQ ID NO: 14	
G13top	TTAAGCAATTGATGCTACAGTGAATTCCG SEQ ID NO: 15	Gpa1/G <sub>α13</sub>
G13btm	TCGACGGAATTCAGTGTAGCATCAATTGC SEQ ID NO: 16	
G14top	TTAAGGAATTTAACTTGGTTTGAATTCCG SEQ ID NO: 17	Gpa1/G <sub>α14</sub>
G14btm	TCGACGGAATTCAAACCAAGTTAAATTCC SEQ ID NO: 18	
G16top	TTAAGGAAATTAACCTATTGTGAATTCCG SEQ ID NO: 19	Gpa1/G <sub>α16</sub>
G16btm	TCGACGGAATTCACAATAGGTTAATTTCC SEQ ID NO: 20	
Stoptop	TTAAGTGAGCGGCCGCGAATTCCG SEQ ID NO: 21	[truncated Gpa1p]
Stopbtm	TCGACGGAATTCGCGGCCGCTCAC SEQ ID NO: 22	

The resulting plasmids encoded in-frame fusions between amino acids 1 to 467 of Gpa1p and the 5 C-terminal acids of mammalian G<sub>α</sub> subunits (Fig.5C). A plasmid to express a truncated version of Gpa1 lacking the 5 C-terminal acids (Fig.5D) was created by introducing a stop codon at codon position 468 by insertion of linkers as above (Table 1).

## 10 Yeast Strains

The yeast strain MMY9 was created to study the functional interactions between 7 transmembrane helix receptors and G proteins. This strain was derived from the common laboratory strain W303-1A (genotype: *MATa his3 ade2 leu2 trp1 ura3 can1*). Activation of the pheromone response pathway was monitored by two reporter genes, *FUS1-HIS3* and *FUS1-lacZ* which were integrated into the *FUS1* and *leu2* loci, respectively. The *FAR1* gene was deleted by one-step gene replacement using a *far1Δ::URA3* DNA construct, so that growth continued even under conditions which activated the pheromone response pathway. The *SST2* gene was deleted by one-step gene replacement using a *sst2Δ::URA3* DNA construct to prevent down-regulation of G protein signalling by the GTPase-activating function encoded by this gene. After each of these manipulations, the *ura3* marker was recovered by transformation with a *ura3Δ* fragment consisting of the of the *URA3* gene with an internal 243bp (*EcoRV* to *StuI*) deletion, followed by 5-fluoro-orotic acid selection. The chromosomal *GPA1* (G<sub>α</sub>) gene

was deleted by one-step gene replacement using a *gpa1Δ::ADE2* DNA construct.

5 The yeast strain MMY11 was derived from MMY9 by one-step gene replacement using a *ste2Δ::G418<sup>R</sup>* DNA construct, selecting for geneticin resistant colonies and confirming that resistant colonies failed to respond to the Ste2p agonist,  $\alpha$ -factor.

#### 10 Assays for Reporter Gene Expression

Agonists somatostatin (S-14), melatonin, serotonin, adenosine 5'-diphosphate (ADP) and uridine 5'-triphosphate (UTP) were obtained from Sigma. Alpha factor was synthesised by Peptide and Protein Research, Exeter, UK. 5'-N-Ethylcarboxamidoadenosine (NECA) was obtained from Research Biochemicals  
15 International.

**Assay for *FUS1-HIS3* Expression.** Reverse halo assays were carried out by growing MMY9 cells to early stationary phase ( $OD_{600} \approx 4$ ) in liquid SC-glucose (2%) medium lacking tryptophan and uracil. A uniform layer of cells ( $5 \times 10^7$ ) was  
20 plated to 22.5cm by 22.5cm bioassay dishes (Nunc) in 100ml SC-glucose agar (1%) equilibrated to 50°C. This medium lacked tryptophan, uracil and histidine, and was supplemented with 10mM 3-aminotriazole, and buffered to pH 7.0 with 0.1M sodium phosphate. Antibiotic discs were placed on the solidified agar, and a volume of agonist solution (1-5 $\mu$ l) was applied to each disc. Plates were  
25 incubated at 30°C for 3 days.

**Assays for *FUS1-lacZ* Expression.**  $\beta$ -galactosidase activities in cell extracts were measured with two assays. In the first assay (ONPG assay), cell extracts were incubated with the substrate ONPG as described by (37). Units were  
30 defined as  $(A_{420} \times 1000)/(OD_{600} \times t \times v)$  (25). In the chemiluminescent assay, cells were grown to late logarithmic phase and diluted to 0.02  $OD_{600}$  in 100 $\mu$ l SC-WH medium in the presence or absence of 1  $\mu$ M  $\alpha$ -factor in 96-well microtitre plates. After incubation (30°C; 6 hours), 20 $\mu$ l of cells were removed and mixed with 20 $\mu$ l assay mix (125 mM sodium phosphate pH 7.5, 15 mM  
35  $MgSO_4$ , 200  $\mu$ M Galacton-Star  $\beta$ -galactosidase substrate (Tropix), 10% (v/v)

Sapphire II (Tropix), 1 U/ $\mu$ l oxalyticase (Enzogenetics)). After incubation (30°C; 1 hr) chemiluminescence was determined in a Top-count scintillation counter (Packard).

- 5 **Assay for combined *FUS1-lacZ* and *FUS1-HIS3* Expression.** *In vivo* assays of reporter gene induction (CPRG assays) were carried out by suspending cells to 0.02 OD<sub>600</sub> in 200 $\mu$ l SC-glucose (2%) lacking tryptophan, uracil and histidine. This medium was supplemented with agonists, and additionally 10mM 3-aminotriazole and the  $\beta$ -galactosidase (*lacZ*) substrate chlorophenolred- $\beta$ -D-galactopyranoside (CPRG; Boehringer) to a concentration of 0.1mg/ml. To visualise the colour change reaction, the medium was buffered to pH 7 with 0.1 M sodium phosphate. The assay was conducted in a 96-well microtitre plate format. Plates were incubated for 24 hours without agitation, and absorbance at 570nm was determined using a Victor microtitre plate reader (Wallac). EC<sub>50</sub> values (+/- standard error) were estimated by curve-fitting, using the Robosage software package.

Yeast strains used in this study:

Strains	Genotype
W303-1A	<i>MATa his3 ade2 leu2 trp1 ura3 can1</i>
MMY9	<i>W303-1A fus1:FUS1-HIS3 FUS1-lacZ::LEU2 far1<math>\Delta</math>::ura3<math>\Delta</math> gpa1<math>\Delta</math>::ADE2 sst2<math>\Delta</math>::ura3<math>\Delta</math></i>
MMY11	<i>MMY9 ste2<math>\Delta</math>::G418<sup>R</sup></i>

20

#### Experiment 1: Receptors activating yeast pheromone pathway

- This experiment used four human G protein-coupled receptors as examples of receptors capable of activating the yeast pheromone response pathway. The four receptors were: the melatonin ML<sub>1B</sub> receptor, the serotonin 5HT<sub>1A</sub> receptor, the somatostatin SST<sub>2</sub> receptor and the purinergic nucleotide receptor, P2Y<sub>2</sub>. These receptors were expressed in yeast strain MMY9 described above. This strain was deleted for *SST2*, *FAR1* and *GPA1* but retained the endogenous  $\alpha$ -factor receptor encoded by *STE2*. Activation of the pheromone response pathway was monitored with two integrated reporter genes: *FUS1-HIS1* allowing

30



a growth readout in medium lacking histidine, and *FUS1-lacZ* allowing a  $\beta$ -galactosidase readout. These assays are described herein above. We initially investigated signalling of these receptors via the endogenous yeast heterotrimeric G protein (Gpa1p/Ste4p/Ste18p). Receptors were expressed in yeast strain MMY9 from the strong *PGK* promoter, using high copy number episomal vectors. In Fig. 1, panels A-F show a reverse halo assay performed using MMY9 cells co-transformed with the plasmid pRS314-GPA1 (panels B to F), which expresses the wild-type *GPA1* gene and, in addition, with either a receptor expression construct or vector, as follows: pDT-PGK (vector; panel B); pFL61-SST<sub>2</sub> (panel C); pDT-PGK-ML<sub>1B</sub> (panel D); pDT-PGK-P2Y<sub>2</sub> (panel E); pDT-PGK-5-HT<sub>1A</sub> (panel F). Agonist-dependent activation of *FUS1-HIS3* was determined by reverse halo assay in which agonists were applied to the filter discs in the arrangement shown in panel A, in quantities as follows: 3 nmol of somatostatin-14 (S-14); 40 nmol of melatonin (Mel); 3 nmol of  $\alpha$ -factor; 100 nmol of UTP; 40 nmol of serotonin (5-HT). As expected, treatment of MMY9 cells with the yeast pheromone,  $\alpha$ -factor, stimulates the endogenous yeast receptor Ste2p, resulting in increased expression of *FUS1-HIS3* to enable a halo of cell growth in the absence of histidine (Fig. 1, Panel B). Similarly, MMY9 cells expressing the ML<sub>1B</sub> receptor (panel D) activated *FUS1-HIS3* in response to melatonin, as well as in response to  $\alpha$ -factor. Cells expressing the SST<sub>2</sub> receptor (panel C) responded to somatostatin, and cells expressing the P2Y<sub>2</sub> receptor (panel E) responded to the agonist UTP. The zones of cell growth in Fig. 1 are comparable in size, although different molar quantities of agonist were required for each receptor. Thus, the ML<sub>1B</sub>, SST<sub>2</sub> and P2Y<sub>2</sub> receptors can couple to the yeast pheromone response pathway, via activation of the endogenous G $\alpha$ , Gpa1p. MMY9 cells transformed with the 5-HT<sub>1A</sub> receptor expression construct did not activate *FUS1-HIS3* in response to the agonist serotonin, suggesting that this receptor interacts poorly or cannot functionally interact with Gpa1p.

#### Experiment 2: Yeast/Mammalian Chimera coupling to receptors

This experiment illustrates that, for certain receptors, the efficiency of coupling to the yeast pheromone response pathway can be enhanced by creating chimeras between yeast and mammalian G $\alpha$  subunits. A series of chimeric G $\alpha$  subunits was generated in which the C-terminal domain (C-terminal 142 amino

acids) of Gpa1p was replaced with corresponding regions of rat  $G_{\alpha 0}$ ,  $G_{\alpha 1}$ ,  $G_{\alpha 2}$  and  $G_{\alpha 3}$  (Fig. 5(b)). To achieve an appropriate stoichiometry of G protein subunits, the chimeras were encoded on centromeric plasmids and expressed from the promoter of the *GPA1* gene. This avoids quenching of the  $G_{\beta}/G_{\gamma}$ -mediated signal, due to excess  $G_{\alpha}$  (33). These constructs were used in an experiment in which MMY9 cells were cotransformed with pairs of plasmids, one expressing a  $G_{\alpha}$  subunit and the second either vector (pDT-PGK) or one of the receptor expression constructs pFL61-SST<sub>2</sub>, pDT-PGK-ML<sub>1B</sub>, pDT-PGK-P2Y<sub>2</sub> or pDT-PGK-5-HT<sub>1A</sub>. Agonist-dependent activation of *FUS1-lacZ* was determined by incubating cells in medium supplemented with the chromogenic, cell-permeant  $\beta$ -galactosidase (*lacZ*) substrate, chlorophenolred- $\beta$ -D-galactopyranoside (CPRG; Boehringer Mannheim). The extent of conversion of this substrate after 24 hr incubation at 30°C was determined by spectrophotometry and the results for the yeast  $G_{\alpha}$  and the four chimeras are shown in Fig 2 A-D: 2A Ste2p receptor (pDT-PGK - transformed cells); 2B SST<sub>2</sub> receptor (pFL61-SST<sub>2</sub>); 2C ML<sub>1B</sub> receptor (pDT-PGK- ML<sub>1B</sub>); 2D 5-HT<sub>1A</sub> receptor (pDT-PGK-5-HT<sub>1A</sub>).

As expected,  $\alpha$ -factor stimulated the endogenous Ste2p receptor resulting in induction of *FUS1-lacZ* and provoking the strongest response with Gpa1p ( $EC_{50}$ ; 5.2  $\pm$  0.4 nM). This value is consistent with the reported affinity of Ste2p for  $\alpha$ -factor peptide ( $K_d$ ; 17 nM) (3). MMY9 cells expressing the Gpa1/ $G_{\alpha 0}$  and Gpa1/ $G_{\alpha 2}$  chimeras also induced *FUS1-lacZ* in response to high concentrations of  $\alpha$ -factor, but dose-response curves were displaced rightwards by at least two log units, suggesting that the Ste2p receptor interacts less efficiently with these chimeras than with wild-type Gpa1p. MMY9 cells expressing Gpa1/ $G_{\alpha 1}$  or Gpa1/ $G_{\alpha 3}$  chimeras did not induce *FUS1-lacZ* in response to  $\alpha$ -factor. In contrast, the somatostatin SST<sub>2</sub> receptor was coupled to the pheromone response pathway by all the  $G_{\alpha i}$  chimeras ( $EC_{50}$  values: 430  $\pm$  44 nM; 300  $\pm$  38 nM; 650  $\pm$  65 nM; 300  $\pm$  22 nM; and 630  $\pm$  30 nM for respectively Gpa1p, Gpa1/ $G_{\alpha 0}$ , Gpa1/ $G_{\alpha 1}$ , Gpa1/ $G_{\alpha 2}$ , and Gpa1/ $G_{\alpha 3}$ ). This confirms that the chimeric  $G_{\alpha}$  subunits are functional, and suggests that failure of receptors to couple to the pheromone response pathway is due to incompatibility with the  $G_{\alpha}$  C-terminal region. We confirmed that the chimera proteins were produced at levels comparable to wild-type Gpa1p by quantitative Western blotting (data not

shown), using a polyclonal antibody directed against the N-terminus of Gpa1p which is common to all these proteins.

5 Of the other receptors, 5-HT<sub>1A</sub> and ML<sub>1B</sub> both exhibited more efficient coupling to the pheromone response pathway in cells expressing chimeric G<sub>α</sub> subunits than those expressing Gpa1p. The 5-HT<sub>1A</sub> receptor adopts a conformation in yeast capable of activating Gpa1/G<sub>α0</sub>, supporting the hypothesis from Experiment 1 that this receptor is incompatible or poorly compatible with Gpa1p. Strikingly, the  
10 receptors are specific for particular chimeras, for example ML<sub>1B</sub> activates Gpa1/G<sub>αi2</sub> but not Gpa1/G<sub>αi3</sub>, even though these chimeras differ at just 14 amino acid positions, and levels of expression are similar in each case. When signalling was mediated by wild-type Gpa1p, *FUS1-lacZ* was induced to a lesser extent by P2Y<sub>2</sub> than the other receptors (data not shown), consistent with the requirement for greater molar quantities of agonist to give a similar zone of  
15 growth in the reverse halo assay (Fig. 1). The P2Y<sub>2</sub> agonist response was not enhanced by any of the G<sub>αi</sub> chimeras (data not shown).

### Experiment 3: Chimeras with C-terminal regions of G<sub>α16</sub>

20 The G<sub>α15</sub>/G<sub>α16</sub> subunits are reported to interact with a much broader range of receptors than is typical for a G<sub>α</sub> subunit, and have the ability to couple receptors which normally interact with G<sub>αi</sub>, G<sub>αs</sub> or G<sub>αq</sub> (26). A Gpa1/G<sub>α16</sub> C-terminal domain chimera, if it exhibited similar properties to full-length G<sub>α16</sub>, might be expected to couple diverse receptors to the pheromone response  
25 pathway. We constructed a plasmid encoding a Gpa1/G<sub>α16</sub> C-terminal domain chimera (pRS314- Gpa1/G<sub>α16</sub>; Fig. 5(b); Fig. 6(h)) derived from the same centromeric vector as used for expression of functional chimeras described above. The level of *FUS1-LacZ* induction in MMY9 cells expressing the Gpa1/G<sub>α16</sub> chimera was determined by preparing cell extracts, and incubating  
30 them with the LacZ substrate o-Nitrophenyl β-D-galactopyranoside (ONPG; see Materials and Methods). Gpa1/G<sub>α16</sub> reduced *FUS1-LacZ* expression resulting in β-galactosidase activity of 79 +/- 8 units (Table 2). This level was intermediate between the activity of control cells transformed with vector (239 +/- 30 units), in which the pathway is constitutively activated due to the absence of G<sub>α</sub>, and the  
35 basal activity in cells producing wild-type Gpa1p (19 +/- 4 units). Therefore, the

pheromone response pathway was partially activated, suggesting that this construct, which directs expression of Gpa1/G<sub>α16</sub> from the *GPA1* promoter, fails to sequester all free G<sub>β</sub>/G<sub>γ</sub>.

- 5 Table 2: Gpa1/G<sub>α16</sub> binds yeast G<sub>β</sub>/G<sub>γ</sub> but fails to support coupling of the Ste2p receptor.

G protein	Promoter	No Alpha Factor	Plus Alpha Factor	n
Vector		239 +/- 30	224 +/- 44	5
GPA1	<i>GPA1</i>	19 +/- 4	273 +/- 49	3
GPA1/G16	<i>GPA1</i>	79 +/- 8	79 +/- 4	3
GPA1/G16	<i>TEF1</i>	23 +/- 5	24 +/- 8	5
GPA1/G16	<i>GPD1</i>	16 +/- 4	13 +/- 4	3

- 10 We made further constructs to express Gpa1/G<sub>α16</sub> from the stronger *TEF1* and *GPD1* promoters. These reduced *FUS1-lacZ* expression to levels comparable to those in Gpa1p-producing cells (Table 1). In Fig. 3, MMY9 cells transformed with the different Gpa1/G<sub>α16</sub> expression constructs, or control plasmids were streaked to a non-selective agar plate supplemented with histidine (panel A) and to a
- 15 selective agar plate lacking histidine and supplemented with 3-aminotriazole (panel B). The *TEF*-Gpa1/G<sub>α16</sub> and *GPD*-Gpa1/G<sub>α16</sub> expression constructs reduced *FUS1-HIS3* reporter gene expression to prevent growth on histidine-selective medium in common with the positive control plasmid (pRS314-GPA1), which expresses wild-type *GPA1*. In contrast, the Gpa1/G<sub>α16</sub> expression
- 20 construct which utilised the *GPA1* promoter (pRS314-Gpa1/G<sub>α16</sub>) failed to reduce *FUS1-HIS3* expression sufficiently to prevent growth under histidine-selective conditions, similar to the situation with vector-transformed cells (control). This result agrees with the ONPG assay results tabled above, therefore, the two reporter genes, *FUS1-lacZ* and *FUS1-HIS3*, behave similarly.

- 25 With none of the Gpa1/G<sub>α16</sub> expression constructs, however, did the Ste2p receptor appear to be coupled to the pheromone response pathway, because

treatment of cells with  $\alpha$ -factor did not induce *FUS1-LacZ* (Table 1). MMY9 cells expressing the other receptors ( $ML_{1B}$ ,  $5-HT_{1A}$ ,  $P2Y_2$ , or  $SST_2$ ) in combination with  $Gpa1/G_{\alpha16}$  also did not exhibit agonist-dependent induction of *FUS1-LacZ* (data not shown). Therefore, even though  $Gpa1/G_{\alpha16}$  can prevent the yeast  $G_{\beta}/G_{\gamma}$  particle from activating the pheromone response pathway, presumably by assembling into a G protein trimer, no free  $G_{\beta}/G_{\gamma}$  is released in the presence of activated receptors. Clearly, the approach of constructing this type of chimera, containing a large C-terminal domain derived from a mammalian  $G_{\alpha}$  subunit fused to the N-terminal region of  $Gpa1p$ , is not generally applicable to all  $G_{\alpha}$  subunits, but is successful with some  $G_{\alpha}$  subunits (including the  $G_{\alpha i}$  family and  $G_{\alpha s}$ ) but not others (such as  $G_{\alpha16}$ ). The  $Gpa1/G_{\alpha16}$  chimera lacks the important property of full-length  $G_{\alpha16}$ , that of coupling a much broader range of receptors than other  $G_{\alpha}$  subunits. This experiment confirms that  $Gpa1/G_{\alpha16}$  C-terminal domain chimeric protein is produced in cells, and thus that its failure to couple G protein-coupled receptors to the pheromone response pathway is likely to be due to incompatibility between receptor and this  $G_{\alpha}$  subunit.

A  $Gpa1/G_{\alpha s}$  chimera has been reported to couple the growth hormone releasing hormone receptor (12) when expressed from the strong constitutive promoter of the yeast phosphoglycerate kinase (*PGK1*) gene. We constructed  $Gpa1/G_{\alpha s}$  and  $Gpa1/G_{\alpha q}$  chimeras similar to those described above (Fig.5B) and expressed them in MMY9 cells from the promoter of the *GPA1* gene. We assayed *FUS1-LacZ* activity in these cells using a chemiluminescent assay, rather than the ONPG assay described above. Results are presented in Table 3. As expected from the previous experiments, cells expressing  $Gpa1/G_{\alpha16}$  from the *GPA1* promoter exhibited significantly higher activities than control cells expressing  $Gpa1p$ .  $Gpa1/G_{\alpha s}$  and  $Gpa1/G_{\alpha q}$  chimeras are similar to  $Gpa1/G_{\alpha16}$  in that they also have significantly higher activities than control cells expressing  $Gpa1p$ . In contrast, cells expressing  $Gpa1/G_{\alpha0}$ ,  $Gpa1/G_{\alpha i1}$ ,  $Gpa1/G_{\alpha i2}$ , or  $Gpa1/G_{\alpha i3}$  from the *GPA1* promoter as expected contained activities comparable to control cells expressing  $Gpa1p$ . In this experiment only wild-type  $Gpa1p$  and the  $Gpa1/G_{\alpha0}$  chimera coupled the  $Ste2p$  receptor, as shown by increased *FUS1-LacZ* levels in cells incubated with 1  $\mu$ M  $\alpha$ -factor. This is consistent with the results of the CPRG assay above. This experiment further confirms that the  $Gpa1/G_{\alpha0}$ ,  $Gpa1/G_{\alpha i1}$ ,  $Gpa1/G_{\alpha i2}$ , or  $Gpa1/G_{\alpha i3}$  chimeras may be expressed from the *GPA1*

promoter and result in sufficiently low activation of the pheromone response pathway in the absence of activated receptor to be able to detect coupling, but that the Gpa1/G<sub>as</sub>, Gpa1/G<sub>aq</sub> and Gpa1/G<sub>α16</sub> chimeras may not.

5 **Table 3: Activity of the pheromone response pathway in MMY9 cells expressing chimeric G<sub>α</sub> subunits**

G <sub>α</sub> subunit	FUS1-LacZ Activity			
	No factor	α-	1 μM	α-
[vector]	8.7±2.0		7.4±1.6	
Gpa1p	0.73±0.25		27.2±1.7	
Gpa1/G <sub>α1</sub>	0.71±0.2		0.68±0.15	
Gpa1/G <sub>α2</sub>	0.66±0.33		0.67±0.34	
Gpa1/G <sub>α3</sub>	0.50±0.22		0.76±0.23	
Gpa1/G <sub>α0</sub>	0.44±0.12		0.75±0.069	
Gpa1/G <sub>α16</sub>	3.6±1.9		3.6±1.5	
Gpa1/G <sub>as</sub>	3.1±2.0		5.0±3.0	
Gpa1/G <sub>aq</sub>	8.2±3.9		9.6±4.1	

10 Values are mean ± SD light units (x10<sup>6</sup> cps) in the chemiluminescent β-galactosidase assay. n ≥ 5.

#### Experiment 4: Transplant Approach

15 Fusions with longer N-terminal regions of Gpa1p and shorter regions of mammalian G<sub>α</sub> subunits than the chimeras described above might still alter receptor specificity, given that minor modifications to the C-terminus of mammalian G<sub>α</sub> subunits can change receptor specificity (7)(40)(23)(18). This could avoid the problem of chimeras having reduced affinity for G<sub>β</sub>/G<sub>γ</sub>. We created a refined set of Gpa1-G<sub>α</sub> fusions, designated the "transplants" (to distinguish them from the chimeras having longer regions of mammalian G<sub>α</sub> (Fig 20 5(B)). These fusions had the five C-terminal residues (<sup>468</sup>KIGII<sup>COOH</sup>) of Gpa1p

replaced by the five C-terminal residues of  $G_{\alpha 16}$  (EINLL<sup>COOH</sup>),  $G_{\alpha q}$  (EYNLV<sup>COOH</sup>) or  $G_{\alpha s}$  (QYELL<sup>COOH</sup>)(see Fig. 5(C)). MMY9 cells were co-transformed with the transplant constructs, and in addition with pDT-PGK (vector with no heterologous receptor) or the receptor expression constructs pDT-PGK-5-HT<sub>1A</sub>, pFL61-SST<sub>2</sub> or pDT-PGK-P2Y<sub>2</sub>. As in Experiment 2, agonist-dependent activation of *FUS1-LacZ* was determined by incubating cells in medium supplemented with CPRG, and the extent of conversion to product after 24 hr incubation at 30°C was determined by spectrophotometry. The results are depicted in Fig. 4 A-D. This experiment shows that the transplants were able to interact efficiently with  $G_{\beta}/G_{\gamma}$ , since they reduced *FUS1-LacZ* expression in MMY9 cells to basal levels when expressed from the *GPA1* promoter (Fig. 4A). In contrast to the C-terminal domain chimeras of Experiments 2 and 3, the Gpa1- $G_{\alpha 16}$ , Gpa1- $G_{\alpha q}$  and Gpa1- $G_{\alpha s}$  transplants all retained the ability to couple the activated Ste2p receptor to the pheromone response pathway, although the dose-response curves suggested that compared to Gpa1p, the transplants interacted less efficiently with Ste2p ( $EC_{50} = 257 \pm 13$  nM;  $75 \pm 2$  nM;  $102 \pm 5$  nM; respectively for Gpa1- $G_{\alpha s}$ , Gpa1- $G_{\alpha 16}$  and Gpa1- $G_{\alpha q}$ )(Fig. 4A). With human receptors as opposed to the yeast receptor, the transplants improved  $G_{\alpha}$  subunit/receptor interactions. The Gpa1- $G_{\alpha q}$  transplant significantly enhanced coupling of the P2Y<sub>2</sub> receptor relative to Gpa1p, consistent with the finding that P2Y<sub>2</sub> signals to its effector phospholipase C $\beta$  via  $G_{\alpha q}$  in mammalian cells. In contrast, the capacity of the Gpa1- $G_{\alpha s}$  transplant to couple P2Y<sub>2</sub> to the pheromone pathway was indistinguishable from that of Gpa1p.

The Gpa1- $G_{\alpha 16}$  transplant enhanced the agonist response of cells expressing three of the four human receptor (SST<sub>2</sub>, 5-HT<sub>1A</sub>, and P2Y<sub>2</sub> but not ML<sub>1B</sub>). MMY9 cells coexpressing the Gpa1- $G_{\alpha 16}$  transplant with the SST<sub>2</sub> receptor required roughly ten-fold less somatostatin to elicit a similar response to control cells producing Gpa1p ( $EC_{50} = 27 \pm 0.8$  nM for Gpa1- $G_{\alpha 16}$ ;  $EC_{50} = 430 \pm 44$  nM for Gpa1p). The 5-HT<sub>1A</sub> receptor failed to signal in MMY9 cells through wild-type Gpa1p, but did so moderately well through the Gpa1- $G_{\alpha 16}$  transplant. For the SST<sub>2</sub> receptor, the Gpa1- $G_{\alpha 16}$  transplant was the most efficient  $G_{\alpha}$ ; for the 5-HT<sub>1A</sub> and P2Y<sub>2</sub> receptors, the Gpa1- $G_{\alpha 16}$  transplant could support coupling but

not as efficiently as the Gpa1/G $\alpha_0$  chimera and the Gpa1-G $\alpha_q$  transplant, respectively.

It has been reported (34) that deletion of the *STE2* gene encoding the Ste2p  $\alpha$ -factor receptor can result in enhanced coupling efficiencies of heterologously expressed receptors. This may be due to competition between the receptors for G-protein trimers. To investigate the effect of receptor competition on the function of receptors and G $\alpha$  subunits described herein, we constructed a derivative of MMY9 in which the the *STE2* gene was deleted by integrative disruption with the G418<sup>R</sup> resistance marker. The new strain was designated MMY11. This strain was used in an experiment in which MMY9 and MMY11 cells were transformed with the Gpa1p expression construct pRS314-GPA1 (Fig. 6C) and incubated with varying concentrations of  $\alpha$ -factor in a CPRG assay (Fig.7). As expected, MMY11 fails to respond to  $\alpha$ -factor.

MMY11 was used in an experiment in which cells were transformed with pairs of plasmids as before, one to express a G $\alpha$  subunit and the other a receptor expression construct. This experiment involved the four receptor expression constructs previously described herein (pFL61-SST<sub>2</sub>, pDT-PGK-ML<sub>1B</sub>, pDT-PGK-P2Y<sub>2</sub> and pDT-PGK-5-HT<sub>1A</sub>) and four further receptor expression constructs: pDT-PGK-SST<sub>5</sub>, pDT-PGK-A<sub>2b</sub>, pDT-PGK-P2Y<sub>1</sub> and pDT-PGK-5-HT<sub>1D</sub>. We constructed further transplant constructs to express modified versions of Gpa1p in which the C-terminal five amino acids were replaced with those of G $\alpha_0$  (GCGLY<sup>COOH</sup>), G $\alpha_{i1}$  (DCGLF<sup>COOH</sup>), G $\alpha_{i3}$  (ECGLY<sup>COOH</sup>), and G $\alpha_{14}$  (EFNLV<sup>COOH</sup>). These were used in this experiment, along with the G $\alpha$  subunit expression constructs previously described herein. Cells were subjected to CPRG assays to determine the concentration response curve to agonist for each combination of receptor and G $\alpha$  subunit. Where pheromone response pathway activation was detected, the agonist concentration required to yield a half-maximal response (EC<sub>50</sub> +/- standard error; all values in nM except where otherwise indicated) was determined by curve-fitting, and is shown in Table 4A. Where weak activation insufficient to carry out curve-fitting was detected, this is indicated in Table 4A (weak). Where no coupling was detected, this is also indicated (NC).



For comparison, Table 4B presents similar data obtained in MMY9; thus differences between the values in Tables 4A and 4B are likely to be due to the effect of Ste2p on signalling by heterologously expressed receptors.

Table 4A (MMY11):

	chimeras				transplants							
	Gpa1 p	Gpa1/ G $\alpha_0$	Gpa1/ G $\alpha_{11}$	Gpa1/ G $\alpha_{12}$	Gpa1/ G $\alpha_{13}$	Gpa1/ G $\alpha_q$	Gpa1/ G $\alpha_0$	Gpa1/ G $\alpha_{11}$	Gpa1/ G $\alpha_{13}$	Gpa1/ G $\alpha_s$	Gpa1/ G $\alpha_{14}$	Gpa1/ G $\alpha_{16}$
SST2	69±2	46±2	91±6	30±2	47±1	weak	65±4	5.6±0.6	1.8±0.1	NC	49±0.5	7.0±0.6
SST5	26±0.8	115±4	137±8	56±3	97±4	66±3	11±0.5	4.9±0.2	3.6±0.2	weak	19±0.5	3.8±0.1
5-HT <sub>1A</sub>	weak	390±14	11±0.5 $\mu$ M	2.5±0.2 $\mu$ M	7±0.5 $\mu$ M	weak	1.0±0.1 $\mu$ M	1.3±0.1 $\mu$ M	1.1±0.05 $\mu$ M	weak	1.7±0.1 $\mu$ M	1.7±0.1 $\mu$ M
5-HT <sub>1D</sub>	NC	2.0±1.1 $\mu$ M	3.4±1.6 $\mu$ M	355±82	1.8±0.5 $\mu$ M	NC	weak	227±20	135±12	NC	NC	weak
ML1B	912±300	weak	weak	407±200	NC	NC	500±200	14±5	26±5	NC	NC	1.4±0.15 $\mu$ M
P2Y <sub>1</sub>	NC	NC	NC	NC	NC	27±14 $\mu$ M	NC	weak	weak	NC	12±2.5 $\mu$ M	NC
P2Y <sub>2</sub>	weak	NC	NC	NC	NC	3.8±0.1 $\mu$ M	18±2 $\mu$ M	5.2±0.5 $\mu$ M	2.0±0.2 $\mu$ M	weak	3.3±0.08 $\mu$ M	4.64±0.0 $\mu$ M
A2B	43±2	NC	NC	NC	NC	197±8	51±2.5	16±0.8	87±8	30±2.3	56±1.9	40±3

Values in nM except where otherwise indicated.

Table 4B (MMY9):

	chimeras					transplants						
	Gpa1/ p	Gpa1/ G <sub>α0</sub>	Gpa1/ G <sub>α11</sub>	Gpa1/ G <sub>α12</sub>	Gpa1/ G <sub>α13</sub>	Gpa1/ G <sub>α9</sub>	Gpa1/ G <sub>α0</sub>	Gpa1/ G <sub>α11</sub>	Gpa1/ G <sub>α13</sub>	Gpa1/ G <sub>α5</sub>	Gpa1/ G <sub>α14</sub>	Gpa1/ G <sub>α16</sub>
Ste2p	$5.2 \pm 0.4$	$2 \pm 0.1 \mu\text{M}$	weak	$21 \pm 2 \mu\text{M}$	NC	$102 \pm 5$	$31 \pm 4$	$87 \pm 1.5$	$14 \pm 2$	$257 \pm 13$	$288 \pm 50$	$75 \pm 2$
SST2	$430 \pm 44$	$300 \pm 38$	$650 \pm 65$	$300 \pm 22$	$630 \pm 30$	weak	ND	ND	ND	NC	ND	$27 \pm 0.8$
5-HT1A	NC	$2.6 \pm 0.4 \mu\text{M}$	weak	weak	weak	weak	ND	ND	ND	weak	ND	weak
ML1B	$5.3 \pm 0.3 \mu\text{M}$	weak	weak	$1.4 \pm 0.2 \mu\text{M}$	NC	NC	ND	ND	ND	NC	ND	weak
P2Y2	weak	NC	NC	NC	NC	$3.6 \pm 0.4 \mu\text{M}$	ND	ND	ND	weak	ND	$16 \pm 0.6 \mu\text{M}$

Values in nM except where otherwise indicated. ND indicates not determined.

This experiment further illustrates that coupling efficiencies can be substantially enhanced by this "transplant" type of modification, even compared to the chimeric Gpa1/G $\alpha$  subunits described in Experiments 2 and 3. Coupling of the Ste2p receptor was supported by all of the transplants, although none were as effective as wild-type Gpa1p, as indicated by the greater concentrations of  $\alpha$ -factor required to elicit half-maximal responses (Table 4B). However, the transplants in general enhanced the coupling of human receptors, relative to wild-type Gpa1p (Table 4A) as indicated by the lower concentrations of agonists required to elicit half-maximal responses. All of the transplants enhanced P2Y<sub>2</sub> signalling except Gpa1-G $\alpha$ <sub>S</sub>, which was not significantly different from wild-type Gpa1p. Most efficient was the Gpa1-G $\alpha$ <sub>i3</sub> transplant. Similarly, the transplants enhanced the efficiency of coupling of the SST<sub>2</sub>, SST<sub>5</sub>, ML<sub>1B</sub>, 5HT<sub>1D</sub> and A<sub>2b</sub> receptors, relative to either Gpa1p or to the chimeras with long C-terminal domains of G $\alpha$ <sub>i/o</sub>, often with ten-fold or greater reductions in EC<sub>50</sub>. The P2Y<sub>1</sub> receptor could be coupled to the pheromone response pathway only by transplants, with the Gpa1-G $\alpha$ <sub>14</sub> transplant being most efficient. It is informative to compare the Gpa1/G $\alpha$ <sub>i2</sub> chimera and Gpa1-G $\alpha$ <sub>i1</sub> transplant, which differ only in the length of sequence derived from the mammalian G $\alpha$  (as the C-terminal five amino acids of G $\alpha$ <sub>i1</sub> and G $\alpha$ <sub>i2</sub> are identical). The EC<sub>50</sub> values for ML<sub>1B</sub> and SST<sub>2</sub> were more than ten-fold greater with the Gpa1-G $\alpha$ <sub>i1</sub> transplant than with the Gpa1/G $\alpha$ <sub>i2</sub> chimera. The same comparison can be made for the Gpa1/G $\alpha$ <sub>i3</sub> chimera and Gpa1-G $\alpha$ <sub>i3</sub> transplant. Clearly, chimeras with shorter lengths of mammalian G $\alpha$  subunits can give more efficient coupling of some receptors. The only receptor in this study for which a transplant did not yield optimal coupling efficiency was 5HT<sub>1A</sub> where the most efficient transplant was Gpa1-G $\alpha$ <sub>0</sub> (EC<sub>50</sub> in MMY11; 1.0 $\pm$ 0.1  $\mu$ M) but the most efficient coupling was achieved with the Gpa1/G $\alpha$ <sub>0</sub> chimera (EC<sub>50</sub> in MMY11; 390 $\pm$ 14 nM). This suggests that for the majority of mammalian receptors, most efficient coupling in yeast will be achieved with the transplant type of G $\alpha$  subunit.

Comparison of EC<sub>50</sub> values obtained in MMY9 and MMY11 for identical combinations of receptor and G $\alpha$  subunit indicates that the absence of Ste2p can enhance coupling efficiencies by approximately 10-fold. Moreover, for certain poorly compatible receptor/G-protein combinations coupling could be detected in

MMY11 but not in MMY9, for example 5HT<sub>1A</sub> and Gpa1p. This is fully consistent with the previously observed effects of deleting the *STE2* gene, reported by Price *et al.* (34), and does not affect the conclusions above.

5 We created a further construct to express a truncated Gpa1p molecule lacking the five C-terminal amino acids (Fig.8D). This truncation mutant has been reported to bind G $\beta$ /G $\gamma$  but fail to couple Ste2p to the pheromone response pathway (11). As expected, expression of this truncated Gpa1p mutant in MMY9 or MMY11 cells resulted in low levels of *FUS1-LacZ* activity, indicating the  
10 truncated mutant can bind G $\beta$ /G $\gamma$  (data not shown). In the CPRG  $\beta$ -galactosidase assay, this mutant fails to couple either Ste2p or other receptors to the pheromone response pathway (data not shown). This is fully consistent with the report of Hirsch *et al.* (11) and confirms the importance of the five C-terminal amino acids of the G $\alpha$  subunit in the interaction with G-protein coupled  
15 receptors.

We made further transplant constructs to express modified versions of Gpa1p in which the C-terminal five amino acids were replaced with those of G $\alpha_{\text{az}}$  (YIGLC<sup>COOH</sup>), G $\alpha_{12}$  (DIMLQ<sup>COOH</sup>) and G $\alpha_{13}$  (QLMLQ<sup>COOH</sup>). The Gpa1-G $\alpha_{\text{az}}$ ,  
20 Gpa1-G $\alpha_{13}$  and to a lesser extent the Gpa1-G $\alpha_{12}$  transplants expressed from the pRS314-Gpa1-G $\alpha_{\text{az}}$ , pRS314-Gpa1-G $\alpha_{13}$ , and pRS314-Gpa1-G $\alpha_{12}$  constructs were all able to couple the Ste2p receptor but they failed to fully sequester G $\beta$ /G $\gamma$  as they were associated with increased basal levels of *FUS1-LacZ* activity even in the absence of receptor activation (Fig.8). Conceivably, this  
25 might be due to disrupted interaction with G $\beta$ /G $\gamma$ , or to activation by an endogenous yeast protein, or reduced plasmid stability (see below). Quantitative immunoblotting suggested that all transplant proteins were produced to similar levels. We created further plasmids in which the Gpa1-G $\alpha_{\text{az}}$ , Gpa1-G $\alpha_{13}$  and Gpa1-G $\alpha_{12}$  expression cassettes were contained in pRS304. The plasmid  
30 pRS304 is an integrating vector whereas pRS314 is an episomal, centromeric vector. The pRS304-Gpa1-G $\alpha_{\text{az}}$ , pRS304-Gpa1-G $\alpha_{13}$ , and pRS304-Gpa1-G $\alpha_{12}$  constructs were transformed into MMY11, targetting their integration into the *trp1* locus of this strain. The resultant strains expressed the Gpa1-G $\alpha_{\text{az}}$ , Gpa1-G $\alpha_{13}$  and Gpa1-G $\alpha_{12}$  transplants from genes located chromosomally rather than from  
35 genes located on free, episomal plasmids. In the experiment presented in Figure

8, MMY11 cells were transformed with either pRS304-based or pRS314-based (integrating and episomal, respectively) plasmids to express Gpa1-G<sub>αz</sub> (Fig.8A), Gpa1-G<sub>α13</sub> (Fig.8B), or Gpa1-G<sub>α12</sub> (Fig.8C) transplants. In addition, cells were transformed with Yep24-STE2 to express the *STE2* gene, as this had been  
 5 deleted from the MMY11 strain. Activation of *FUS1-LacZ* in response to different concentrations of α-factor was determined in a CPRG assay. This experiment shows that integrating the transplant expression constructs into the chromosome reduces basal levels of *FUS1-LacZ* activity in the absence of receptor activation. This enables the Gpa1-G<sub>αz</sub>, Gpa1-G<sub>α13</sub> and Gpa1-G<sub>α12</sub> transplants to be tested  
 10 in experiments with the human receptor expression constructs for their ability to couple heterologously expressed receptors (data not shown).

We carried out the same approach, of transferring the transplant expression cassette to a pRS304 plasmid and integrating into the genome of MMY11, for  
 15 other transplants. This created a series of strains expressing chromosomal copies of the Gpa1-G<sub>αO</sub>, Gpa1-G<sub>α1</sub>, Gpa1-G<sub>α3</sub>, Gpa1-G<sub>α14</sub>, Gpa1-G<sub>αS</sub>, Gpa1-G<sub>αq</sub>, Gpa1-G<sub>α16</sub>, Gpa1-G<sub>αz</sub>, Gpa1-G<sub>α13</sub> and Gpa1-G<sub>α12</sub> transplants. In all cases, we observed the phenomenon described above, of reduced basal levels of *FUS1-LacZ* activity in the absence of receptor activation, without affecting EC<sub>50</sub>.  
 20 We conclude from this result that the episomal G<sub>α</sub> subunits constructs are unstable. We postulate that in a population of cells containing an episomal G<sub>α</sub> plasmid, a small proportion of cells may lose this plasmid. These cells would not be propagated as they lack the *URA3* gene. However, because they would lack any G<sub>α</sub> subunit the pheromone response pathway would be constitutively  
 25 activated and they would accumulate the LacZ enzyme. Thus elevated basal *FUS1-lacZ* levels would be apparent in the whole population, without changing apparent protein levels. With the integrated copy of the gene encoding G<sub>α</sub>, this does not occur.

30 The set of strains containing the full range of integrated transplants represents the full diversity of known mammalian G<sub>α</sub> subunits likely to be relevant to drug discovery (G<sub>αt</sub> and G<sub>αolf</sub> transplants have not been tested). The same approach of constructing transplants may be taken with any G<sub>α</sub> subunits discovered in the future.

5 In conclusion, this approach represents a significant improvement over previously described technologies, because i) it is applicable to a wider range of  $G_{\alpha}$  subunits, ii) it is applicable to  $G_{\alpha 16}$  in particular and iii) the Gpa1- $G_{\alpha 16}$  transplant possesses, at least to some degree, the property of  $G_{\alpha 16}$  of interacting with a broad range of receptors, and therefore may be the  $G_{\alpha}$  subunit of choice for coupling orphan receptors, for which the physiologically relevant G protein targets are unknown.

## Bibliography

1. Baldwin, J. M. 1994. *Current Opinion in Cell Biology* **6**:180-190.
- 5 2. Bertin, B., et.al. 1992. *Journal of Biological Chemistry* **267**:8200-8206.
3. Blumer, K. J. and J. Thomer. 1990. *Proc. Natl. Acad. Sci. U. S. A.* **87**:4363-4367.
- 10 4. Bourne, H. R. 1997. *Current Opinion in Cell Biology* **9**:134-142.
5. Butkerait, P., et.al. 1995. *Journal of Biological Chemistry* **270**:18691-18699.
6. Cerione, R. A., et.al. 1988. *J. Biol. Chem.* **263**:9345-9352.
- 15 7. Conklin, B. R., et.al. 1993. *Nature* **363**:274-276.
8. Fargin, A., et.al. 1991. *Cellular Signalling* **3**:547-557.
- 20 9. Hamm, H. E., et.al. 1988. *Science* **241**:832-835.
10. Hamm, H. E., et.al. 1987. *J. Biol. Chem.* **262**:10831-10838.
11. Hirsch, J. P., et.al. 1991. *Genes & Development* **5**:467-474.
- 25 12. Kajkowski, E. M., et.al. 1997. *Journal of Receptor & Signal Transduction Research* **17**:293-303.
13. Kallal, L. and J. Kurjan. 1997. *Molecular & Cellular Biology* **17**:2897-2907.
- 30 14. Kang, Y. S., et.al. 1990. *Molecular & Cellular Biology* **10**:2582-2590.
15. Kleuss, C., et.al. 1993. *Science* **259**:832-834.
- 35 16. Kleuss, C., et.al. 1992. *Science* **358**:424-426.



17. Koelle, M. R. 1997. *Current Opinion in Cell Biology* **9**:143-147.
18. Komatsuzaki, K., et.al. 1997. *FEBS Letters* **406**:165-170.
- 5 19. Lambright, D. G., et.al. 1996. *Nature* **379**:311-319.
20. Leberer, E., et.al. 1997. *Current Opinion in Genetics & Development* **7**:59-66.
- 10 21. Lee, C. H., et.al. 1995. *Molecular Pharmacology* **47**:218-223.
22. Lichtarge, O., et.al. 1996. *Proc. Natl. Acad. Sci. U. S. A.* **93**:7507-7511.
- 15 23. Liu, J., et.al. 1995. *Proc. Natl. Acad. Sci. U. S. A.* **92**:11642-11646.
24. Maniatis, T., et.al.. 1982. *Molecular Cloning, A Laboratory Manual*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- 20 25. Miller, J. H. 1972. *Experiments in Molecular Genetics*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
26. Milligan, G., et.al. 1996. *Trends in Pharmacological Sciences* **17**:235-237.
- 25 27. Minet, M., et.al.. 1992. *Plant Journal* **2**:417-422.
28. Oliner, J. D., et.al.. 1993. *Nucleic. Acids. Res.* **21**:5192-5197.
29. Onrust, R., et.al. 1997. *Science* **275**:381-384.
- 30 30. Palm, D., et.al. 1990. *FEBS Lett.* **261**:294-298.
31. Parr, C. E., et.al. 1994.. *Proc. Natl. Acad. Sci* **91**:3275-3279.
- 35 32. Parr, C. E., et.al. 1994. *Proc. Natl. Acad. Sci.* **91**:13067.

33. Price, L. A., et.al. 1995. Molecular & Cellular Biology **15**:6188-6195.
34. Price, L. A., et.al. 1996. Molecular Pharmacology **50**:829-837.
- 5 35. Rasenick, M. M., et.al. 1994. J. Biol. Chem. **269**:21519-21525.
36. Simonds, W. F., et.al.. 1989. Proc. Natl. Acad. Sci. U. S. A. **86**:7809-7813.
- 10 37. Slater, M. R. and E. A. Craig. 1987. Molecular & Cellular Biology **7**:1906-1916.
38. Tesmer, J. J., et.al. 1997. Cell **89**:251-261.
- 15 39. Van Dop, C., G. et.al. 1984. J. Biol. Chem. **259**:23-26.
40. Voyno-Yasenetskaya, T., et.al. 1994. J. Biol. Chem. **269**:4721-4724.
41. Wall, M. A., et.al. 1995. Cell **83**:1047-1058.

CLAIMS.

1. A chimeric  $G_{\alpha}$  protein having yeast  $G_{\alpha}$  (Gpa1p) amino acid sequences modified by a minimum of 3 amino acids positions within the C-terminal 10 amino acids by substitution by alternative amino acids  
5
2. A chimeric  $G_{\alpha}$  protein according to claim 1 wherein the amino acid sequences are modified by at least 5 amino acid positions within the C-terminal 10 amino acids by substitution by alternative amino acids.  
10
3. A chimeric  $G_{\alpha}$  protein having yeast  $G_{\alpha}$  (Gpa1p) amino acid sequences modified at a minimum of three amino acid positions within the C-terminal 10 amino acids by substitution with amino acids from a heterologous  $G_{\alpha}$  protein.  
15
4. A chimeric  $G_{\alpha}$  protein according to claim 3 wherein the amino acid sequence is modified by at least 5 amino acid positions within the C-terminal 10 amino acids by substitution with amino acids from a heterologous  $G_{\alpha}$  protein.  
20
5. A nucleotide sequence encoding a chimeric  $G_{\alpha}$  protein according to any of claims 1 or 4.
6. A transformed yeast cell comprising a nucleotide sequence which encodes a heterologous G protein-coupled receptor and a nucleotide sequence according to claim 5.  
25
7. A method of screening for a compound able to interact with a receptor comprising contacting a compound of interest with a cell according to claim 6 and observing the growth response of the cell.  
30
8. A method according to claim 7 wherein the cell further comprises a reporter gene and the method includes the step of observing the production of a reporter gene product.

1/ 23




FIG.1

2/23


**Ste2 Receptor**

FIG.2(a)

3/23


SST<sub>2</sub> Receptor

FIG.2(b)

4/23


ML<sub>1B</sub> Receptor

FIG. 2(c)

5/23


5HT<sub>1A</sub> Receptor

FIG.2(d)



6/23




FIG.3

7/23

## Ste2 Receptor




FIG.4(a)

8/23


5HT<sub>1A</sub> and G16 transplant

FIG. 4(b)

9/23


**SST<sub>2</sub> Receptor**

FIG.4(c)

10/23





FIG.4(d)


11/ 23

# **G<sub>α</sub> proteins**


## **A. Wild-type Gpalp:**



## **B. Gpal/G<sub>α</sub> Chimeras:**



## **C. Gpal/G<sub>α</sub> Transplants:**



## **D. Truncated Gpal:**



**FIG.5**

12/23




FIG. 6(a)

14/23




FIG. 6(c)



15/23




FIG.6(d)

16/23




FIG.6(e)

17/23




FIG.6(f)

18/23




FIG.6(g)

19/23




FIG. 6(h)

20 / 23




FIG.7

21 / 23




FIG.8(a)

22 / 23




FIG.8(b)



23/23




FIG.8(c)

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/02759

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/62 C12N1/19 C07K14/47 C12Q1/68 G01N33/50  
//C07K14/72,C07K14/705

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 21925 A (AMERICAN CYANAMID CO ;PAUSCH MARK HENRY (US); OZENBERGER BRADLEY A) 17 August 1995 cited in the application see abstract see claims 3,4,17,18,22,27 ---	1-8
A	CONKLIN B.R: ET AL.: "Carboxyl-terminal mutations of Gq alpha and Gs alpha that alter the fidelity of receptor activation" MOLECULAR PHARMACOLOGY, vol. 50, no. 4, October 1996, pages 885-890, XP002090508 see the whole document --- -/--	1-8

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 January 1999

Date of mailing of the international search report

03/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Galli, I

# INTERNATIONAL SEARCH REPORT

Int: Jonal Application No

PCT/GB 98/02759

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>W0 98 16557 A (GEN HOSPITAL CORP)</p> <p>23 April 1998</p> <p>see page 3 - page 7</p> <p>see figure 1</p> <p>see claims 1-27</p> <p>-----</p>	1-8

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 98/02759

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9521925 A	17-08-1995	US 5691188 A	25-11-1997
		AU 1846995 A	29-08-1995
		CA 2183166 A	17-08-1995
		EP 0745130 A	04-12-1996
		JP 9510087 T	14-10-1997
		SG 49061 A	18-05-1998
		US 5846819 A	08-12-1998
WO 9816557 A	23-04-1998	NONE	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**